Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

NCT05378464 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

BIOLOGICAL: Dendritic Cell (DC1) Vaccine
DRUG: Trastuzumab
DRUG: Pepinemab
BIOLOGICAL: T-Cell therapy

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]